Effects of bisacodyl on ascending colon emptying and overall colonic transit in healthy volunteers.
BACKGROUND
The mechanism of action of bisacodyl in the unprepared human colon remains unclear.


OBJECTIVE
To evaluate the effect of oral bisacodyl on the overall and regional colonic transit in humans.


METHODS
In a double-blind, randomized, placebo-controlled study of 25 healthy participants, effects of oral bisacodyl (5 mg p.o. per day) and placebo on colonic transit were compared. A validated scintigraphy method was used to measure colonic transit. The primary transit endpoints, ascending colon emptying t(1/2) and geometric centre of colon isotope at 24 h (overall transit), were compared (Wilcoxon rank sum test).


RESULTS
There were significant treatment effects on ascending colon t(1/2), with the bisacodyl group demonstrating accelerated emptying [median 6.5 h, interquartile range 5.0-8.0 h] relative to the placebo group [11.0 h (7.0-17.1); P = 0.03]. Numerical differences in colonic geometric centre 24 h [bisacodyl median 3.0 (2.2-3.8), placebo 4.0 (3.1-4.6)] were not significant (P = 0.19). There were no significant differences observed in geometric centre 4 h.


CONCLUSIONS
Oral 5 mg bisacodyl accelerates ascending colon in the unprepared colon in healthy adults; this action may contribute to the drug's efficacy in constipation.
Manabe
N
N
Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER), Mayo Clinic, Rochester, MN 55905, USA.
Cremonini
F
F
Camilleri
M
M
Sandborn
W J
WJ
Burton
D D
DD
D000293:Adolescent; D000328:Adult; D001726:Bisacodyl / Q000627:therapeutic use*; D002400:Cathartics / Q000627:therapeutic use*; D044682:Colon, Ascending / Q000000981:diagnostic imaging / Q000187:drug effects*; D004311:Double-Blind Method; D005260:Female; D005772:Gastrointestinal Transit / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011877:Radionuclide Imaging; D016896:Treatment Outcome; D055815:Young Adult
D002400:Cathartics; D001726:Bisacodyl
Gastroenterology. 1991 Jul;101(1):107-15
2044899
Aliment Pharmacol Ther. 2006 May 15;23(10):1479-88
16669963
Gut. 1988 Aug;29(8):1085-92
3410334
Lancet. 2000 Mar 25;355(9209):1035-40
10744088
Am J Physiol Gastrointest Liver Physiol. 2009 Feb;296(2):G295-301
19033530
Aliment Pharmacol Ther. 1995 Feb;9(1):69-73
7766747
Neurogastroenterol Motil. 2004 Aug;16(4):397-402
15305994
Arzneimittelforschung. 1988 Apr;38(4):570-4
3401271
Gastroenterology. 2000 Jul;119(1):41-50
10889153
Can J Physiol Pharmacol. 1986 Jan;64(1):39-43
3955442
Digestion. 1999 Jan-Feb;60(1):69-73
9892801
Gastroenterology. 2001 Feb;120(2):354-60
11159875
Gastroenterology. 1978 Apr;74(4):698-703
631507
Eur J Pharmacol. 1985 Nov 5;117(2):215-22
4076344
Digestion. 1984;30(3):191-4
6548720
J Nucl Med. 1997 Nov;38(11):1807-10
9374360
Int J Colorectal Dis. 2008 Dec;23(12):1175-83
18665373
Drugs Aging. 1998 Sep;13(3):245-53
9789728
Aliment Pharmacol Ther. 2002 Oct;16(10):1781-90
12269971
Am J Gastroenterol. 2005 Apr;100(4):936-71
15784043
Int J Pharm. 2000 Feb 25;196(1):11-20
10675703
Mayo Clin Proc. 1990 Nov;65(11):1456-79
2232900
Am J Physiol Gastrointest Liver Physiol. 2006 May;290(5):G942-7
16603730
Naunyn Schmiedebergs Arch Pharmacol. 1972;274(1):46-53
4262724
N Engl J Med. 1993 Oct 7;329(15):1073-8
8371728
Scand J Gastroenterol. 2008;43(5):545-50
18415746
Gastroenterology. 2007 Sep;133(3):761-8
17854590
Gut. 1974 Aug;15(8):599-607
4419566
Am J Physiol. 1990 Jun;258(6 Pt 1):G856-62
2360632
Aliment Pharmacol Ther. 2001 Oct;15(10):1655-66
11564007
J Pharmacol Exp Ther. 1994 Sep;270(3):1239-45
7523656
Dig Dis Sci. 2003 Jul;48(7):1206-12
12870774
Gastroenterology. 1992 Jul;103(1):36-42
1612355
Digestion. 1987;37(4):247-53
3678638